Silence Therapeutics
SLN
29 hedge funds and large institutions have $110M invested in Silence Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
4% more funds holding
Funds holding: 28 → 29 (+1)
0.33% less ownership
Funds ownership: 17.39% → 17.07% (-0.33%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
60% less capital invested
Capital invested by funds: $277M → $110M (-$167M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$5.96M |
| 2 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$983K |
| 3 |
LOAME
Lombard Odier Asset Management (Europe)
London,
United Kingdom
|
+$887K |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$331K |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.7M |
| 2 |
Morgan Stanley
New York
|
-$1.63M |
| 3 |
Axa
Paris,
France
|
-$1.48M |
| 4 |
SG Americas Securities
New York
|
-$1.34M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$249K |
SLN Hedge Fund Activity: Q1 2023 in Review
29 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q1 2023, worth a combined $110M — down 60% from $277M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SLN positions and 2 closed out — a net gain of 1 holder — while 9 added to existing stakes and 7 trimmed.
The largest buyer was Artal Group, opening a new position worth an estimated $5.96M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $10.7M sold.
- 29 institutional investors held Silence Therapeutics (SLN) as of Q1 2023, up from 28 in Q4 2022.
- Funds reported $110M of Silence Therapeutics stock for Q1 2023, down 60% quarter-over-quarter.
- 3 funds opened new Silence Therapeutics positions in Q1 2023 and 2 closed out, a net change of +1 holder.
- The largest Silence Therapeutics buyer in Q1 2023 was Artal Group, an estimated $5.96M added.
- The largest Silence Therapeutics seller in Q1 2023 was Adage Capital Partners, an estimated $10.7M sold.
Based on aggregated 13F filings for Q1 2023.